IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Name: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
License: Public Domain

University of California, Davis

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

high risk non-muscle invasive bladder urothelial carcinoma, stage 0a bladder cancer ajcc v8, stage 0is bladder cancer ajcc v8, stage i bladder cancer ajcc v8

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 314325
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.